journal article·2021-05-12

Dual-Stimuli Responsive Polymeric Micelles for the Effective Treatment of Rheumatoid Arthritis

Liming He, Xianyan Qin, Donghao Fan, Chenglan Feng, Qin Wang, Jiyu Fang

ACS Applied Materials & Interfaces· Volume 13· Issue 18
Publisher page

Abstract

The nontargeted distribution and uncontrolled in vivo release of drugs impede their efficacy in the treatment of rheumatoid arthritis (RA). Delivering drugs to arthritic joints and releasing drugs on demand are a feasible solution to achieve the effective treatment of RA. In this paper, we report a facile method to assemble dual-stimuli responsive polymeric micelles from polyethylene glycol-phenylboric acid-triglycerol monostearate (PEG-PBA-TGMS, PPT) conjugates with the aim of delivering dexamethasone (Dex) to arthritic joints and controlling the release of Dex by inflammatory stimuli. We show that the release of Dex from the PPT micelles is accelerated in response to acidic pH and overexpressed matrix metalloproteinases. In an adjuvant-induced arthritis model, the PPT micelles preferentially accumulate in arthritic joints and show an excellent therapeutic efficacy after being intravenously administrated. Our results highlight the potential of the dual stimuli-responsive micelles as a promising therapeutic option for the effective treatment of inflammatory diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Rheumatoid Arthritis Research and Therapies · Advancements in Transdermal Drug Delivery · Orthopedic Infections and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Advanced Technologies of Materials, Ministry of Education and School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China

Advanced Materials Processing and Analysis Center and Department of Materials Science and Engineering, University of Central Florida, Florida 32816, United States

Funding

National Natural Science Foundation of China

References (48)

Show source-provided references
1. 10.1097/BOR.0b013e32832a2f0210.1097/BOR.0b013e32832a2f02 ↗
2. 10.1016/j.addr.2012.03.00610.1016/j.addr.2012.03.006 ↗
3. 10.1039/C7BM00254H10.1039/C7BM00254H ↗
4. 10.1038/nrd.2016.2110.1038/nrd.2016.21 ↗
5. 10.1038/nrdp.2018.110.1038/nrdp.2018.1 ↗
6. 10.1093/rheumatology/kes11510.1093/rheumatology/kes115 ↗
7. 10.1007/s12274-018-2233-310.1007/s12274-018-2233-3 ↗
8. 10.1038/nrrheum.2015.810.1038/nrrheum.2015.8 ↗
9. 10.2217/nnm.15.4510.2217/nnm.15.45 ↗
10. 10.3390/molecules2401014610.3390/molecules24010146 ↗
11. 10.1021/acsnano.9b0171010.1021/acsnano.9b01710 ↗
12. Andersson S. E. · J. Rheumatol. · 1999 · 26 · 2018
13. 10.1002/biot.20180002410.1002/biot.201800024 ↗
14. 10.1038/nrrheum.2016.6910.1038/nrrheum.2016.69 ↗
15. 10.1007/s00296-010-1592-110.1007/s00296-010-1592-1 ↗
16. 10.1016/j.bmc.2007.01.01110.1016/j.bmc.2007.01.011 ↗
17. 10.2174/138161282566619032110442410.2174/1381612825666190321104424 ↗
18. 10.1038/nmat377610.1038/nmat3776 ↗
19. 10.1002/adhm.20190028310.1002/adhm.201900283 ↗
20. 10.1021/acsabm.0c0088310.1021/acsabm.0c00883 ↗
21. 10.1016/j.ejps.2016.12.01110.1016/j.ejps.2016.12.011 ↗
22. 10.1016/j.jconrel.2019.12.02510.1016/j.jconrel.2019.12.025 ↗
23. 10.1016/j.jconrel.2020.09.04410.1016/j.jconrel.2020.09.044 ↗
24. 10.1016/j.jconrel.2016.12.02710.1016/j.jconrel.2016.12.027 ↗
25. 10.1038/natrevmats.2016.7510.1038/natrevmats.2016.75 ↗
26. 10.1021/acs.nanolett.9b0534010.1021/acs.nanolett.9b05340 ↗
27. 10.1002/art.3793210.1002/art.37932 ↗
28. 10.1016/j.actbio.2020.09.02610.1016/j.actbio.2020.09.026 ↗
29. 10.1016/j.ijpharm.2019.11862510.1016/j.ijpharm.2019.118625 ↗
30. 10.1038/s41467-018-03691-110.1038/s41467-018-03691-1 ↗
31. 10.1021/acsami.9b1713710.1021/acsami.9b17137 ↗
32. 10.1016/j.biopha.2016.03.00410.1016/j.biopha.2016.03.004 ↗
33. 10.1016/j.biomaterials.2020.12057410.1016/j.biomaterials.2020.120574 ↗
34. 10.1021/acsabm.0c0024210.1021/acsabm.0c00242 ↗
35. 10.1016/j.jconrel.2016.03.03510.1016/j.jconrel.2016.03.035 ↗
36. 10.1002/adma.20150631210.1002/adma.201506312 ↗
37. 10.1039/C4NR04796F10.1039/C4NR04796F ↗
38. 10.1016/j.biomaterials.2016.01.00810.1016/j.biomaterials.2016.01.008 ↗
39. 10.1002/mabi.20160013610.1002/mabi.201600136 ↗
40. 10.1016/j.ijpharm.2020.11978710.1016/j.ijpharm.2020.119787 ↗
41. 10.1016/j.carbpol.2019.11580310.1016/j.carbpol.2019.115803 ↗
42. 10.1039/C9RA08169K10.1039/C9RA08169K ↗
43. 10.1016/j.msec.2020.11125010.1016/j.msec.2020.111250 ↗
44. 10.1016/j.ajps.2020.07.00510.1016/j.ajps.2020.07.005 ↗
45. 10.1186/s12951-020-00604-710.1186/s12951-020-00604-7 ↗
46. 10.1002/art.2445310.1002/art.24453 ↗
47. 10.1038/nrrheum.2017.11510.1038/nrrheum.2017.115 ↗
48. 10.1080/10717544.2018.144705010.1080/10717544.2018.1447050 ↗